Abstract

According to axilla sentinel lymph node lymphatic drainage pattern, we hypothesized that internal mammary sentinel lymph node (IM-SLN) receives lymphatic drainage from not only the primary tumor area, but also the entire breast parenchyma. Based on the hypothesis a modified radiotracer injection technique was established and could increase the visualization rate of the IM-SLN significantly. To verify the hypothesis, two kinds of tracers were injected at different sites of breast. The radiotracer was injected with the modified technique, and the fluorescence tracer was injected in the peritumoral intra-parenchyma. The location of IM-SLN was identified by preoperative lymphoscintigraphy and intraoperative gamma probe. Then, internal mammary sentinel lymph node biopsy (IM-SLNB) was performed. The fluorescence status of IM-SLN was identified by the fluorescence imaging system. A total of 216 patients were enrolled from September 2013 to July 2015. The overall visualization rate of IM-SLN was 71.8% (155/216). The success rate of IM-SLNB was 97.3% (145/149). The radiotracer and the fluorescence tracer were identified in the same IM-SLN in 127 cases, the correlation and the agreement is significant (Case-base, rs=0.836, P<0.001; Kappa=0.823, P<0.001). Different tracers injected into the different sites of the intra-parenchyma reached the same IM-SLN, which demonstrates the hypothesis that IM-SLN receives the lymphatic drainage from not only the primary tumor area but also the entire breast parenchyma.

Highlights

  • Internal mammary lymph node (IMLN) metastasis has a similar prognostic importance as axillary lymph node (ALN) involvement in breast cancer patients [1,2,3]

  • Different tracers injected into the different sites of the intra-parenchyma reached the same internal mammary sentinel lymph node (IM-SLN), which demonstrates the hypothesis that IM-SLN receives the lymphatic drainage from the primary tumor area and the entire breast parenchyma

  • The overall visualization rate of IM-SLN detected by preoperative lymphoscintigraphy and gamma probe was 71.8% (155/216). 96.1% (149/155) of them received internal mammary sentinel lymph node biopsy (IM-SLNB)

Read more

Summary

Introduction

Internal mammary lymph node (IMLN) metastasis has a similar prognostic importance as axillary lymph node (ALN) involvement in breast cancer patients [1,2,3]. Internal mammary sentinel lymph node biopsy (IM-SLNB) was a minimally invasive technique for the efficient evaluation of the status of internal mammary sentinel lymph nodes (IM-SLN) with high safety and feasibility [4, 5]. The success rate of IM-SLNB has reached 60-100% with minimal or no changes in operative time [4,5,6,7], but the visualization rate of IM-SLN was low (average 13%, range 0-37%) by the traditional injection technique [6,7,8]. To avoid more injury by complete IMLN dissection following IM-SLNB, an alternative validation study for the hypothesis was performed: two different tracers were injected in different sites of the intra-parenchyma to observe whether they could reach to the same IM-SLN

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call